BPC-157 - Hubio Pharm

BPC-157 entered research in 1992 under Croatian scientist Predrag Sikiric. Synthesized from a protein in gastric fluid, it was studied for healing properties in soft and connective tissues. Funding came from Pliva Pharmaceuticals until 2005, when financial support ended. Merck later tried but failed to secure rights. Although it never reached formal medical approval, BPC-157 is now widely distributed in the research market, with Slovenian company Diagen as a leading supplier.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about BPC-157 by Hubio Pharm, consult with your doctor or healthcare professional.